The AACR NextGen Grants for Transformative Cancer Research represent the AACR’s flagship funding initiative to stimulate highly innovative research from young investigators. 2017 NextGen grantee, Hani Goodarzi, PhD, shares the impact of this grant on his career and on metastasis research, especially in colorectal cancer.
The AACR-Novocure Tumor Treating Fields Research Grants represent a joint effort to promote and support innovative research focused on Tumor Treating Fields (TTFields), which are intermediate frequency, low intensity, alternating electric fields that disrupt cell division in cancer cells. 2020 grant recipient Carsten Hagemann, PhD, shares his perspectives on the myriad benefits of the grant.
Researchers have been trying to get a better understanding of the biodistribution and durability of the CAR T response once inside the body. Two recent publications in Cancer Research and Clinical Cancer Research have reported on two different kinds of PET imaging techniques to monitor the CAR T cells inside the body.
Despite demonstrated success in many solid tumor types, immune checkpoint blockade (ICB) agents have minimal efficacy in high grade serous ovarian cancer (HGSC). In this study, the authors describe a novel bispecific anti-PD-1/PD-L1 antibody, which showed increased anti-tumor efficacy compared to mono-specific anti-PD-1 or anti-PDL1. The researchers also...
AACR has been the Scientific Partner of Stand Up To Cancer (SU2C) since 2008. It supports the scientific oversight, expert peer review and administration of many SU2C-funded grants. To keep the scientific community informed of the impact of this scientific partnership, a subset of research articles published by SU2C-funded scientists are summarized.
AACR grantee Sergey Karakashev, PhD, and colleagues at the Wistar Institute have recently shown that the efficacy of PARP inhibitors can be extended to HR-proficient epithelial ovarian cancers using a combinatorial approach with inhibitors of the histone-modifying enzyme EZH2.